glp 1 being discontinued Older Americans Quit Weight Loss Drugs in Droves FDA says that the GLP-1

The progression of semaglutide from a metabolic drug to a potential neuroprotective agent is ongoing, but its future role in neurology will likely focus on the prevention of neurodegeneration rather than the treatment of established diseases

The cerebrolysin group showed statistically significant improvements across multiple measures: the Sandoz Clinical Assessment Geriatric scale, self-assessment scores, cognitive performance measures, and concentration testing for elderly patients

Clinical incidence rates per the FDA Wegovy label: nausea (44%), diarrhoea (23%), vomiting (15%), constipation (11%)

J., Vilsboll, T

Nakanishi, H